FibroGen Gets Grant for Sickle Cell Disease Research
Posted on: Wednesday, 23 August 2006, 12:00 CDT
FibroGen has received a phase II Small Business Innovation Research grant from the US National Institutes of Health that provides continued support for the development of FibroGen hypoxia-inducible factor prolyl hydroxylase inhibitors as therapeutic agents to treat sickle cell disease.
FibroGen is already conducting multiple phase II clinical studies of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors that stimulate erythropoiesis for the treatment of anemia, including the company's lead candidate, FG-2216, in the settings of chronic kidney disease and cancer.
Erythropoietic HIF-PH inhibitors increase the body's endogenous production of erythropoietin, a hormone that stimulates the production of red blood cells, normalizes iron regulation, and reduces the adverse effects of inflammatory cytokines that otherwise suppress the formation of healthy red blood cells.
The sickle cell disease (SCD) research program at FibroGen seeks to combine the erythropoietic effects of HIF-PH inhibitors with the additional capacity to elevate fetal hemoglobin (HbF).
Work conducted under the phase II Small Business Innovation Research (SBIR) grant will focus on the identification of HIF-PH inhibitors that are effective in raising HbF either alone or in combination with hydroxyurea in a model of chronic anemia. From these studies, a HIF-PH inhibitor will be selected as a therapeutic candidate for clinical testing in patients with SCD.
The rationale underlying FibroGen's HIF-PH inhibitor therapeutic program for SCD is guided by published reports demonstrating that the expression of HbF can be induced in primates, including humans, by exposure to hypoxic conditions.
Source: Datamonitor
Related Articles
- NeoPharm Signs IL-13 Related CRADA With NINDS/ NIH for Research on the Therapeutic Agent for Untreatable Brain Diseases
- PHC Initiates Phase I Alzheimer's Disease Trial
- PHC's Pivotal Research Initiates Largest Phase I Alzheimer's Disease Trial to Date for Major National Sponsor
- Aethlon Medical Signs Cooperative Research and Development Agreement With The U.S. Army Medical Research Institute of Infectious Diseases
- Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax(TM) Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
- Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study; Conference Call Begins at 1:00 P.M. Eastern Time Today
- Foundation for Clinical Research in Inflammatory Bowel Disease Launches MyIBD.Org
- New York Blood Center Praises Passage of Stem Cell Therapeutic & Research Act of 2005 Which Will Help Save Lives of Thousands
- US Researchers Cure Inherited Liver Disease in Rats With Genetherapy
User Comments (0)
RSS Feeds